

ATNAHS Factbook

Our history



What we do



Acquire

We acquire "mature" (i.e. post-patent expiry), branded prescription medicines from large cap and specialty pharma globally



Develop

We develop line extensions (new formulations or new markets) to the medicines we acquire. We also develop our own niche generic medicines in-house



Market

We currently own and market a portfolio of more than 15 medicines in over 130 markets globally

How we do it



Projects

Our dedicated team has vast experience in transitioning medicines seamlessly into our networks, and working with vendors to ensure there is no disruption in supply to patients



NPD

Our chemists work with our other experts to make the most of the medicines we acquire, developing new formulations for new markets. They also work on developing generic medicines



In Line

Once we have transitioned an acquired medicine, our In Line team takes over, making sure we maintain the highest standard of ethical medical practice, manage our supply chain and deliver high-quality medicines to our patients

Our key therapeutic areas



Women's Health

Bonviva® and Gynest®



Pain

Anaprox®, Naprosyn® and Toradol®




Gastro

Dipentum®, Kytril® and Opium NMI (Dropizol®)


Some of our key products



Our markets & offices



Our sales by therapeutic area



Our sales by region

